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INTRODUCTION 1
In recent years the American College of Rheumatology (ACR) 1 , Osteoarthritis Research Society International (OARSI) 2 , 2 American Academy of Orthopaedic Surgeons (AAOS) 3 , National Institute for Health and Care Excellence (NICE) 4 
, 3
European League against Rheumatism (EULAR) 5 and others have developed recommendations through Clinical 4 Practice Guidelines (CPGs) to optimise the treatment of hand, hip and/or knee osteoarthritis (OA) based on a 5 variable combination of expert consensus and systematic review of clinical research evidence. These guidelines have 6 many commonalities, however, uptake has been suboptimal 6,7 . 7 A task force led by the US Chronic Osteoarthritis Management Initiative (COAMI) Work Group of the US Bone and 8 Joint Initiative examined the potential issues and barriers involved in the translation of CPGs to clinical practice 8 . The 9 authors found that information about guideline applicability such as items regarding facilitators and barriers to 10 guideline use, practical advice concerning guideline implementation, resource implications and monitoring/auditing 11 criteria was often not included. A critical review of guidelines published in 2007 stated that in order to improve 12 applicability and to increase uptake by end users, stakeholder opinions and barriers to use need to be taken into 13 account during guideline development 9 . Furthermore, effective delivery of treatments requires clear procedural 14 details of the essential elements of treatment, including how and when they are best administered, but 15 unfortunately, these details are often lacking 10 . 16 A general practitioner survey of adherence to EULAR 2000 recommendations found that the majority of the 17 physicians were aware of OA guidelines (79%) and almost all of them agreed with the recommendations (97%), but 18 only 54% adhered to the pharmacological and non-pharmacological recommendations 11 . These findings suggest a 19 deficiency of methods to operationalize and disseminate the existing recommendations in target populations across 20 specialties, particularly in general practice. With this insight, the 2014 version of the NICE guideline offered 21 implementation tools and resources to help users put the recommendations into practice; hopefully this 22 advancement will be adopted in future guidelines 4 . The current study offers a different view, as we based our 23
strategy on examples of clinical scenarios in order to bring the recommendations to the reality of clinical practice. 24
The purposes of this exercise were: (i) to harmonize the recent guidelines, searching for common ground among the 25 recommended treatment options for OA and (ii) to develop user-friendly management algorithms for common case 26 scenarios as a method to discuss, prioritise and put into a complex setting/context the different individual 27 recommendations, aiming to facilitate the translation of evidence-based recommendations into practice. The target 28 audience is professionals across countries involved with the primary care of OA but also relevant to secondary care 29 professionals. 30
MATERIALS AND METHODS 31
To accomplish our research objectives we coordinated the exercise in five distinct phases: 32
(1) Participants -invitation of health professionals in the field of OA (OA panel and systematic review panel, 33 described below) and two people living with symptoms of knee OA (public involvement); 34
(2) Systematic review update -update of the appraisal of existing guidelines 8 ; 35 (3) Trustworthy guidelines assessment -assessment of selected guidelines according to the standards for developing 36 trustworthy clinical practice guidelines as established by the National Academy of Medicine (NAM) 12 
Systematic Review Panel 52
A subset of the OA panel (AG, AN, JJ, KA and YG) corresponded to the previous authors of a comprehensive 53 systematic review on clinical practice guidelines for OA management 8 . The role of this panel was to provide a critical 54 appraisal of existing treatment guidelines through the update of their previous systematic review by including the 55 most recent guidelines and respective recommendations. 56
Trustworthy Guidelines Assessors 57
The 16 guidelines were assessed regarding all the criteria and sub-criteria proposed by the NAM for developing 58 trustworthy clinical practice guidelines 12 . The evaluation was made by two assessors (SM and TL). DH acted as 59 moderator in case of disagreement between the assessors. 60
Public involvement 61
Two people with knee OA from Australia were involved in giving feedback throughout the process. They participated 62 in the case scenario formulation, algorithm construction and manuscript development. All comments were 63 considered and incorporated. The participants approved the final version of this manuscript and agreed with its 64 content. All the communications were made via in person meeting or email. 65
Systematic Review Update 66
The design of the systematic review was developed using the guidelines of the Preferred Reporting Items for 67 Systematic Reviews and Meta-Analyses (PRISMA). The PRISMA statement includes a 27-item checklist for use as a 68 basis for reporting systematic reviews 13 . The methodology used here was consistent with the previous work and is 69 presented as supplementary material. A protocol was not registered for this review. 70
Our goal was to update the findings of a previous comprehensive systematic review on clinical practice guidelines for 71 OA management. Our search time frame was restricted to January 1st, 2013 to October 1 st 2014 to overlap the 72 search of this previous comprehensive review, which investigated this topic from January 1 st 2000 to April 1 st 2013 8 . 73 We searched Medline and the Agency for Healthcare Research & Quality (AHRQ) Guidelines Clearinghouse using the 74 keywords "osteoarthritis and practice management". Our search terms differed from the previous review in order to 75 create a more sensitive search given the short time frame between reviews. 76
The overall quality of each included guideline was assessed using the AGREE II instrument (Appraisal of Guidelines 77 for Research and Evaluation, 2 nd edition; www.agreetrust.org). Since the methodological approach to the updates to 78 previous guidelines did not change, the scores from the previous versions were maintained. 79
Trustworthy Guidelines Assessment 80
In March 2011, the NAM established standards for developing Trustworthy Clinical Practice Guidelines (CPGs), in 81 order to examine the quality and trustworthiness of clinical practice guidelines and how they can be improved to 82 enhance healthcare quality and patient outcomes 12 The guidelines used in the updated systematic review were assessed regarding all the criteria and sub-criteria. The 87 evaluation was conducted by two assessors (SM and SL). In the first meeting, a table with the NAM standards and 88 the electronic copy of the guidelines were provided. After both assessors independently evaluated the compliance of 89 all guidelines to NAM criteria and completed the table, a second meeting was scheduled in order to verify 90 disagreements. All conflicting answers were discussed until a consensus was reached between the two assessors. 91
The remaining conflicting answers were discussed with a moderator (DH) at a third meeting in order to produce a 92 final consensus. After this meeting, valid answers for trustworthy CPG were established. 93
Case Scenarios 94
The OA panel produced four case scenarios for the most affected joints: hand (1), knee (2) and hip OA (1). Aspects 95 like symptoms, comorbidities and previous treatment response were included in the scenario in order to be 96 consistent with what occurs in clinical practice. DH developed the first draft. All authors and the two consumers with 97 OA provided feedback through email over four rounds and they discussed all issues until consensus was reached. DH 98 produced the final version. 99
Algorithms 100
The algorithm development consisted of four steps. First, we only selected the recommendations that were 101 consistent across the guidelines, in other words, we excluded controversial recommendations (i.e. a recommendation advised by one guideline and advised against by another). To do this we extracted the results of 103 the updated systematic review and created a list of homogeneous recommendations. 104 Second, with the recommendations' list in hand we selected the appropriated treatment options for each scenario, 105 considering the comorbidities and treatment contra-indications. 106
The third step was the review and feedback process through email, in which we collected and incorporated all 107 suggestions of co-authors. The OA panel commented on the treatment options and structure of the algorithms. The 108 group discussed all aspects of discordance until a consensus was reached, thus the algorithms were developed using 109 guideline consistency plus expert consensus. The drafts of each algorithm were presented to the consumers with OA 110 for feedback and their comments incorporated. DH resolved the discrepancies and the OA panel approved the final 111 version. 112
The last step was the design elaboration. The arrangement of the algorithm was strategically created to facilitate 113 clinical interpretation. We organised the algorithm structuring the non-pharmacological and pharmacological 114 interventions in parallel and surgical options at the bottom since optimal management for OA requires a 115 combination of conservative non-drug and drug treatments, with surgery reserved for severe clinical disease with 116 structural changes 17 . The intention is to encourage clinicians to offer first non-invasive interventions always 117 cognisant of symptom severity and the level of disability of the patient. Clinical practice varies but in general 118 nonpharmacologic and pharmacologic options are used simultaneously 14 . 119
RESULTS 120

Systematic Review Update 121
After duplicate citations were removed, we screened 101 unique citations (n=84 Medline and n=17 AHRQ) along 122 with the 16 citations included from the previous review. Full-text review occurred for 22 manuscripts. Reasons for 123 exclusion of a guideline after full-text review were: 1) not meeting inclusion criteria (guideline was not OA-specific 124
[n=1] 15 or 2) a guideline was outdated by a more recently available update or revised version [n=5] 16, 17, 18, 19, 20 . After 125 screening and full text review, we included a total of 16 articles describing guidelines for OA management (Figure 1 ). 126
The majority of the included articles were consistent with the previous review (n=15) with two updates (MQIC 21 and 127 NICE 4 ), two revisions (EULAR Hip and Knee 5 and OARSI Knee 2 ) and one additionally identified guideline (Italian 128 Society for Rheumatology 22 ). Five were from the United States 1,3,21,23,24 one from Canada 25 , eight from 129 Europe 4, 5, 22, 26, 27, 28, 29, 30 one from Asia 31 , and one multinational 2 . Most recommendations were directed toward doctors 130 and allied health professionals, and most had multi-disciplinary input from general practitioners, rheumatologists, 131 orthopaedic surgeons, and physiotherapists. Also, a few guidelines received feedback from patient representatives. 132
The various grading scales used by the individual societies for their recommendations are summarized in Table 1  133 (supplementary material). 134
AGREE II 135
Scaled AGREE II scores were derived from the two independent reviewers' scores as a percentage of the maximum 136 possible score. The 6 domain scores are listed separately. The OARSI guidelines scored highest on the overall 137 assessment (75%), followed by the AAOS, ACR, MOVE, and NICE guidelines (all 67%). The highest domain scores were 138 for scope and purpose (description of overall objectives, health questions covered, and target population) and rigor 139 of development (use of systematic methods, clear criteria for study selection, strengths and limitations of evidence 140 described, methods of formulating recommendations described, risks and benefits considered, clear link between 141 recommendation and supporting evidence, external review, and procedure for updates). The lowest domain scores 142 were for applicability. This domain includes items about facilitators and barriers to guideline use, practical advice 143 regarding guideline implementation, resource implications, and monitoring/auditing criteria, which were not often 144 included in the OA guidelines. Several guidelines also did not adequately discuss issues related to editorial 145 independence. 146
The summary of recommendations regarding non-pharmacological interventions can be found in the supplementary 147 material as Table 2 (education and self-management), Table 3 (exercise and weight loss), Table 4 (assistive devices), 148 
Trustworthy Guidelines Assessment 151
All CPGs detailed the development process; however, information regarding the funding source was missing from 152 some. According to NAM standards, the management of Conflicts of Interest (COI) needs to be performed prior to 153 selection of the Guideline Development Group (GDG), and whenever possible the GDG chair should not have a COI.
However, there was only one guideline (AAOS) which completely followed these criteria. Other guidelines presented 155 the authors' COI but included no information about whether COI were declared prior to formation of the GDG. 156
The GDGs were frequently composed of a multidisciplinary group of experts; however, only a few included patient 157 representatives or advocates in the development process. Strategies and incentives to increase the effective 158 participation of patient representatives were only used by two GDGs (OARSI and EULAR 2013). Most CPGs were 159 based on systematic reviews, but did not inform whether the articles met the standards set by the NAM's 160 Committee, and no guideline produced their own systematic review. 161
Regarding the recommendations, most of the CPGs established an evidence foundation, rated evidence strength and 162 the majority articulated them in a standardized form. Only a few CPGs had an external and confidential review 163 process and provided the opportunity for the general public for comment on the draft version prior to final guideline 164 release. The updating process was poorly documented or not presented in the majority of CPGs. All guidelines 165 should document the proposed date and conditions for future review, and regularly monitor the literature base to 166 identify the emergence of new relevant evidence that could potentially affect the validity of the CPG. 167
Algorithm development 168
The algorithm was developed for each case scenario consistent with the evidence from the consensus 169 recommendations within the guidelines (Case Scenario 1, 2, 3 and 4). In order to improve clarity for the general 170 reader we provided the criteria for which we would make a diagnosis of OA. Therefore, for each case, we added the 171 common signs and symptoms based on Map of Medicine Healthguides 32 . We also included a warning box to check 172 for comorbidities with examples of the most frequent conditions. 173
As suggested by the OA panel, the algorithm includes more conservative or less costly treatment approaches prior to 174 more invasive, expensive or potentially harmful interventions, such as: A) Referral to physiotherapist or occupational 175 therapist: the first approach should be group activity/exercise programs available at the patient's community or 176 home exercise program and the referral criteria for therapy should be "if in the clinicians' judgment the patient is 177 weak, stiff or has other functional deficits". B) Assistive devices and orthoses with the condition "if ADL is impaired". For patients with concurrent conditions such as upper GI problems, peptic ulcer and chronic kidney disease we 184 excluded oral non selective nonsteroidal anti-inflammatory drug (NSAID), except in the case 1 where the patient has 185 a past history of upper GI problems; for this case we consider NSAID or cyclooxygenase-2 inhibitors (COX-2), both 186 added to a proton-pump inhibitors (PPI) for gastroprotection in case of failure of acetaminophen treatment. For 187 others, we recommended continued intermittent acetaminophen and topical NSAIDs. Depending on effect and after 188 consideration of potential for harm we recommended considering a COX2 +PPI for other cases where there is 189 concern over GI toxicity. We excluded topical NSAID for the hip case since we believed the drug is incapable of 190 reaching the joint with therapeutic effect. We also excluded drugs previously used by patients that were not 191 effective for them (e.g. In the hip -case 2 algorithm we excluded acetaminophen from the algorithm since the patient 192 reported not experiencing any benefit from intermittent dosing of over the counter acetaminophen). It is worth noting that for the recommendations used during the construction of the algorithm for the hip case, we 205 extrapolated the evidence from knee OA management. The reason for this is that guidelines related to hip OA are 206 usually produced in combination with knee OA and studies involving hip OA only are scarce. 207
DISCUSSION 208
The purpose of this exercise were: (i) to harmonize the recent guidelines, searching for common ground among the 209 recommended treatment options for OA and (ii) to develop user-friendly management algorithms for common case 210 scenarios as a method to discuss, prioritise and put into a complex setting/context the different individual 211 recommendations, aiming to facilitate the translation of evidence-based recommendations into practice. We 212 updated a systematic review and based on recent evidence based recommendations we built an algorithm to 213 address each case scenario. 214
Regarding the trustworthy guidelines assessment, future CPGs should follow the standards proposed by the NAM in 215 order to ensure the quality of the processes supporting development of CPGs. Our analysis suggests that many 216 guidelines still present a lack of transparency, particularly with regards to the management of conflict of interest, 217 external review process and information about planned future updates. It is important to note that all the guidelines 218 used in this paper were not specifically designed to achieve the NAM standards, thus we cannot apply to them the 219 rigour of how the criteria were addressed. The key message is to incentivize future guidelines to address these 220 standards in order to improve quality and transparency. 221
In the updated systematic review, a limited number of additional articles were identified to those included in the 222 previous review by Nelson and colleagues 8 Due to their general consistency, most of the recommendations can be applied in clinical practice. However, at 230 present there is insufficient uptake 6, 7 . Consistent with this concern, our results demonstrate that the lowest domain 231 scores in the AGREE II were for applicability of guidelines. This domain includes important points like discussion of 232 facilitators and barriers to application, provision of advice for practical use, consideration of resource implications, 233 and monitoring/auditing criteria. Poor results in AGREE II were also shown in a 2014 systematic review of non-234 pharmacological management of OA 34 . This lack of focus on the applicability of a CPG seems contradictory to the 235 primary purpose of the guideline in guiding and improving clinical practice. Fortunately, the most recent guidelines 236 seem to better address the domains of the AGREE II 8 . With this in mind, this algorithm exercise is an example of 237 practical use of recommendations in common clinical scenarios to facilitate the practical use of guidelines. In 238 addition, the algorithms establish some criteria to consider for the triage or judicious use of some interventions. 239
Future guidelines could use this methodology in order to facilitate the implementation of recommendations. It is 240 important to note that the AGREE scores reported are based upon the independent views of 2 reviewers and that 241 others may have differing opinions. 242
While people with severe OA symptoms may warrant a combination of treatment modalities, e.g. exercise, 243 pharmacological and potentially surgical interventions, people with mild to moderate OA symptoms should consider 244 non pharmacologic management in the first instance 35, 36 . Guidelines routinely advocate their use but studies suggest 245 that their use in clinical practice is sub-optimal 37 . Our hope is that this study provides guidance on how to extract the 246 information present in guidelines in a logical manner and consequently improve the management of patients with 247
OA. The algorithm is also a visualization of what is often times overly comprehensive guidelines with extensive text 248 that may limit interpretation and ready dissemination. 249
There is a great need for further work in the rational allocation of health resources which besides the clinical 250 judgement must take into account health economic aspects. Therefore, it is important to establish the best way of 251 combining the current evidence on the treatment of osteoarthritis, facilitating this way the construction of an 252 efficient treatment plan and improving the cost-effectiveness of these interventions. With this in mind, the European 253
Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) group proposed a set of 254
disease-specific recommendations on the conduct and reporting of economic evaluations in OA that could help the 255 standardization and comparability of studies that evaluate therapeutic strategies of OA in terms of costs and 256 effectiveness 38 . 257 In this paper, we aimed to rationalise the recommended treatment options considering an ideal management. We 258 are aware that some options indicated are not available for the entire international population, however we 259 considered it important to present what would be the best treatment scenario for each case. We believe that 260 clinicians should opt for the non-pharmacological options prior to the pharmacological pathway; however we know 261 that in the clinical practice this is not the reality. Thus, we chose to organise both treatments in parallel but here we 262 state this hierarchy would represent a better sequence.
In addition, it is important to note that some interventions must be better studied in order to reduce the number of 264 contradictory and inconclusive recommendations among the guidelines. As example, for the hand OA case, due to 265 inconsistency within the guidelines we did not recommend acetaminophen and intra-articular corticosteroid 266 injections. In our case, we solved the conflicts with help of the OA panel. A recent systematic review and meta-267 analysis 39 showed that paracetamol provides minimal short term benefit for people with osteoarthritis. Thus, we 268 decided to offer it as one of the last options on the algorithms. Future guidelines should include this important 269 finding since paracetamol is often the first option among the pharmacological options. 270
Another significant point is that we lack full understanding of who will get the most benefit and least harm for each 271 treatment. On the algorithms we intentionally left the surgical options at the end with a warning that all the other 272 options must be already exhausted before offering the option of surgery. The reason for this is that in spite of 273 universal recommendations for total joint replacement (TJR) in severe cases of OA unresponsive to other therapies, 274 there is insufficient high-quality evidence to support (or quantify) its benefit over the other treatments and there are 275 certainly associated adverse events. 276
Information that is not presented in any guideline is the follow-up period after a joint replacement. We considered it 277 relevant to include this step in all algorithms as: "individualised exercise program aiming for personalized goals for 278 strength, ROM and function regarding the replaced joint and other joints at risk". We believe this is a crucial step in 279 the rehabilitation process and future guidelines should pay more attention to it. Furthermore, we provided in each 280 algorithm a box with clinical signs and symptoms and another with comorbidities check-list. We expect with this to 281 encourage clinicians to diagnose OA based on clinical findings rather than radiological and always consider the 282 comorbidities that the patient might have in order to carefully plan the treatment strategy. 283
There are some important limitations of this work that warrant mention. Firstly, these algorithms are the work of a 284 select group of health professional researchers and do not necessarily reflect the opinions of the organizations that 285 they come from, nor those of others in the field of OA. Another limitation is that only one general practitioner was 286 involved, whereas they are the primary end users. Whilst we appraised and disclosed conflicts of interest, 287 independence from competing interests can never be guaranteed and this paper should be appraised with that 288 caveat in mind. In addition, not all contexts globally are consistent with regards to access to certain interventions, 289 resource implications and barriers to care, so some of the algorithms/interventions may not be optimal or applicable 290 for certain countries. Finally, only guidelines published in English were reviewed, leading to a potential publication 291 bias. We planned to update this paper in three years after it is published or when new evidence suggests the need 292 for modification of clinically important recommendations. 293
CONCLUSIONN 294
In summary, the relative consensus within the guidelines suggests that rather than a lack of quality, there is a failure 295 in the application of the recommendations in clinical practice. The algorithms proposed are examples of how to 296 discuss, prioritise and put into a complex setting/context the different individual recommendations, aiming to 297 facilitate the translation of evidence-based recommendations into practice. 298
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